Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatide.

ABSTRACT:

Importance

Nearly 2% of the US population received a prescription for semaglutide in 2023. There has been a recent concern that this drug and other similar medications may be associated with ophthalmic complications.

Objective

To report ophthalmic complications associated with the use of semaglutide or tirzepatide.

Design, setting, and participants

This was a retrospective case series. All patients were initially seen in a community setting. Patients experiencing an ophthalmic complication in association with the use of semaglutide or tirzepatide were included in this analysis.

Exposures

Patients described were using either semaglutide or tirzepatide.

Main outcomes and measures

Visual acuity and visual field defects.

Results

A total of 9 patients

SUBMITTER: Katz BJ 

PROVIDER: S-EPMC11783245 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature